Baxter

Q2 FY2026 EarningsQ2 FY26 results beat consensus across key metrics, with revenue of $2.96B exceeding the $2.80B expected and adjusted diluted EPS of $0.56 surpassing the $0.37 mean estimate. A significant $0.11 per share benefit from a one-time IEEPA tariff refund drove the bottom-line beat, while organic growth reached 5% despite infusion system shipment holds. Management raised FY26 revenue and adjusted EPS guidance, signaling stronger-than-expected core operating momentum for the remainder of the year.